---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-147884"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:19:19.432425+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics appoints Katharine Knobil, M.D., to Board of Directors

## Summary
- Appointment effective December 8, 2021; Dr. Knobil will serve until 2022 annual meeting.
- Annual cash compensation of $40,000 paid quarterly; initial option for 125,000 shares vesting monthly over three years.
- Dr. Knobil brings 20 years of leadership at GlaxoSmithKline; currently CMO at Agilent Technologies.

## SEC filing metadata
- accession: 0001104659-21-147884
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465921147884/0001104659-21-147884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465921147884/tm2134930d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-147884
- JSON: https://secwatch.observer/filing/0001104659-21-147884.json
- Plain text: https://secwatch.observer/filing/0001104659-21-147884.txt

## Key facts
- Executive change
  Katharine Knobil was appointed as Director at Marker Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective December 8, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Katharine Knobil, M.D. as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465921147884/0001104659-21-147884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.